Bronib^®

Ibrutinib

Product Information

Proprietary Name: Bronib®
Generic Name: Ibrutinib
Dosage Form: Hard Gelatin Capsule
Strengths: 140 mg
Indications: Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), Waldenstrom’s Macroglobulinemia, Marginal Zone Lymphoma, Chronic Graft versus Host Disease

Download Leaflet

Oncology

Bronib®

Ibrutinib is indicated for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), waldenstrom’s macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease.

Apply for a Job Position

Curious about job opportunities?

Signup for a job

Bronib®

Product Information

Bronib®

Apply for a Job Position

Products

Support

Company

Follow Us

Bronib^®